Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine.

CONCLUSION: Decitabine is active in and may benefit patients with > 20% blasts (RAEB-t).
PMID: 23790798 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - June 19, 2013 Category: Cancer & Oncology Authors: Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G Tags: Clin Lymphoma Myeloma Leuk Source Type: research